Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma

Haematologica

Volumn 91, Issue 4, 2006, Pages 542-545

  Van Der Spek, Ellen ^a   Bloem, Andries C ^a   Van De Donk, Niels W C J ^a   Bogers, Lijnie H ^a   Van Der Griend, René ^b   Kramer, Mark H ^c   De Weerdt, Okke ^d   Wittebol, Shulamiet ^c   Lokhorst, Henk M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b DEPARTMENT OF SURGERY   (Netherlands)

^c MEANDER MEDICAL CENTER   (Netherlands)

^d ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Chemotherapy; Lymphoma; Myeloma; Phase I; Statins

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; PREDNISONE; SIMVASTATIN; VINCRISTINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; CONTROLLED STUDY; DEHYDRATION; DEPRESSION; DIARRHEA; DRUG DOSE REGIMEN; DRUG MEGADOSE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HUMAN; KIDNEY DISEASE; LEUKOPENIA; LYMPHOMA; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; MYALGIA; MYELOMA; NAUSEA; NEUTROPENIA; REFRACTORY PERIOD; RHABDOMYOLYSIS; SEPSIS; SEPTIC SHOCK; SUICIDE ATTEMPT; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LYMPHOMA; MAXIMUM TOLERATED DOSE; MULTIPLE MYELOMA; RECURRENCE; SALVAGE THERAPY; SIMVASTATIN; TREATMENT OUTCOME;

EID: 33646004887     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998;97:1453-60.
2. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
3. Reuter CW, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 2000;96:1655-69.
4. van de Donk NW, Kamphuis MM, van Kessel B, Lokhorst HM, Bloem AC. Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. Blood 2003;102:3354-62.
5. Osadchy A, Drucker L, Radnay J, Shapira H, Lishner M. Microenvironment factors do not afford myeloma cell lines protection from simvastatin. Eur J Haematol 2004; 73:183-90.
6. van de Donk NW, Kamphuis MM, Lokhorst HM, Bloem AC. The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 2002;16:1362-71.
7. van de Donk NW, Lokhorst HM, Nijhuis EH, Kamphuis MM, Bloem AC. Geranylgeranylated proteins are involved in the regulation of myeloma cell growth. Clin Cancer Res 2005;11:429-39.
8. van de Donk NW, Schotte D, Kamphuis MM, van Marion AM, van Kessel B, Bloem AC, et al. Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells. Clin Cancer Res 2003; 9:5735-48.
9. Drucker L, Afensiev F, Radnay J, Shapira H, Lishner M. Co-administration of simvastatin and cytotoxic drugs is advantageous in myeloma cell lines. Anticancer Drugs 2004;15:79-84.
10. Schmidmaier R, Baumann P, Simsek M, Dayyani F, Emmerich B, Meinhardt G. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood 2004;104:1825-32.
11. Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002;100:194-9.
12. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996;2:483-91.
13. Larner J, Jane J, Laws E, Packer R, Myers C, Shaffrey M. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol 1998;21:579-83.
14. Kim WS, Kim MM, Choi HJ, Yoon SS, Lee MH, Park K, et al. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 2001;19:81-3.
15. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102:1115-23.
16. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
17. van Stijn A, Kok A, van der Pol MA, Feller N, Roemen GM, Westra AH, et al. A flow cytometric method to detect apoptosis-related protein expression in minimal residual disease in acute myeloid leukemia. Leukemia 2003;17:780-6.